Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir in Treatment-experienced Adolescents and Children With HIV-1
NCT06749054Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of lenacapavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoints: Trough Concentration at Week 26, Treatment-Emergent Adverse Events at Week 26 and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06749054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749054.